RELATED STUDY
The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.
Key Findings: Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity. In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of cannabinoids in the gut and critically determine the course of bowel inflammation and colon cancer.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Austria, Germany
Year of Pub: 2016
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified), Pharma THC, Other Related Compounds
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, TRPV2, PPARs
Ligands Studied: Anti-inflammatory cytokines, Serotonin, Pro-inflammatory cytokines
